Skip to main navigation
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications & Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Stories
    • Patient Stories
    • Disease Focus
      • Overview
      • Transthyretin Amyloidosis
      • Hereditary Angioedema
      • Alpha-1 Antitrypsin Deficiency
      • Hodgkin Lymphoma
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
logo
  • Full-Spectrum Blog
  • Contact
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications &
      Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Focus
    • Patient Stories
    • Disease Focus
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications &
      Presentations
    • Corporate Deck
    • Events &
      Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Investors & Media

Investors & Media

Investor Relations

  • Overview
  • Press Releases
  • Scientific Publications & Presentations
  • Corporate Deck
  • Events & Presentations
  • Press Kit
  • Corporate Governance
  • Financial Info
  • Stock Info
  • Analyst Coverage
  • Investor Resources

Stock Information

  

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
Aug 03, 2023
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Read More
Events & Presentations
More events are coming soon.
Contact IR Contact IR
Email Alerts
RSS Feeds
RSS Feeds
Print Page

Footer Links

  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2023

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.